Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Yokoyama, Waka ^a   Kohsaka, Hitoshi ^a   Kaneko, Kayoko ^a   Walters, Matthew ^b   Takayasu, Aiko ^a   Fukuda, Shin ^a   Miyabe, Chie ^a,c   Miyabe, Yoshishige ^a   Love, Paul E ^d   Nakamoto, Nobuhiro ^e   Kanai, Takanori ^e   Watanabe Imai, Kaori ^a   Charvat, Trevor T ^b   Penfold, Mark E T ^b   Jaen, Juan ^b   Schall, Thomas J ^b   Harigai, Masayoshi ^a   Miyasaka, Nobuyuki ^a   Nanki, Toshihiro ^a,f  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b ChemoCentryx Inc   (United States)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CC CHEMOKINE LIGAND 25; CCX 8037; CD11B ANTIGEN; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CCR9 ANTAGONIST; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG; BETA CHEMOKINE; CC CHEMOKINE RECEPTOR 9; CCL25 PROTEIN, MOUSE; CHEMOKINE RECEPTOR CCR; MOLECULAR LIBRARY; STROMELYSIN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CCL25 GENE; CCR9 GENE; CELL INFILTRATION; CELL LABELING; CELL MIGRATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDY; FIBROBLAST LIKE SYNOVIOCYTE; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MONOCYTE; MOUSE; NONHUMAN; PROTEIN INTERACTION; SPLEEN CELL; SYNOVIOCYTE; SYNOVIUM; WESTERN BLOTTING; ADOPTIVE TRANSFER; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; CYTOLOGY; DBA MOUSE; DRUG EFFECTS; FIBROBLAST; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; SPLEEN;

ADOPTIVE TRANSFER; ANIMALS; ARTHRITIS, EXPERIMENTAL; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES, CC; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 3; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; RECEPTORS, CCR; SMALL MOLECULE LIBRARIES; SPLEEN; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84990876374     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0445-9     Document Type: Article

References (43)

1. Kinne RW, Bräuer R, Stuhlmüller B, Palombo-Kinne E, Burmester GR: Macrophages in rheumatoid arthritis. Arthritis Res 2000, 2:189-202.
2. Goronzy JJ, Weyand CM: Rheumatoid arthritis. Immunol Rev 2005, 204:55-73.
3. Ritchlin C: Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2000, 2:356-360.
4. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T: Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:669-675.
5. Bartok B, Firestein GS: Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010, 233:233-255.
6. Nakano K, Okada Y, Saito K, Tanaka Y: Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum 2004, 50:2450-2458.
7. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S: Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269.
8. Gravallese EM: Bone destruction in arthritis. Ann Rheum Dis 2002, 61:ii84-ii86.
9. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
10. Feldmann M: Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002, 2:364-371.
11. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T: Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:1761-1769.
12. Crawford M, Curtis JR: Tumor necrosis factor inhibitors and infection complications. Curr Rheumatol Rep 2008, 10:383-389.
13. Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M, REAL Study Group: Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 2011, 38:1258-1264.
14. Nishimoto N, Ito K, Takagi N: Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010, 20:222-232.
15. Szekanecz Z, Strieter RM, Kunkel SL, Koch AE: Chemokines in rheumatoid arthritis. Springer Semin Immunopathol 1998, 20:115-132.
16. Koch AE: Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005, 52:710-721.
17. Vergunst CE, Tak PP: Chemokines: their role in rheumatoid arthritis. Curr Rheumatol Rep 2005, 7:382-388.
18. Eksteen B, Adams DH: GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010, 13:472-781.
19. Keshav S, Vanásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, Rácz I, Hetzel D, Nielsen OH, Vermeire S, Reinisch W, Karlén P, Schreiber S, Schall TJ, Bekker P, Prospective Randomized Oral-Therapy Evaluation in Crohn's Disease Trial-1 (PROTECT-1) Study Group: A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One 2013, 8:e60094.
20. Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, Roberts AI, Ebert EC, Kassam N, Qin S, Zovko M, LaRosa GJ, Yang LL, Soler D, Butcher EC, Ponath PD, Parker CM, Andrew DP: Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 1999, 190:1241-1256.
21. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC, Wardlaw AJ, Greenberg HB, Parker CM, Butcher EC, Andrew DP, Agace WW: Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000, 192:761-768.
22. Wurbel MA, Philippe JM, Nguyen C, Victorero G, Freeman T, Wooding P, Miazek A, Mattei MG, Malissen M, Jordan BR, Malissen B, Carrier A, Naquet P: The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double-and single-positive thymocytes expressing the TECK receptor CCR9. Eur J Immunol 2000, 30:262-271.
23. Schmutz C, Cartwright A, Williams H, Haworth O, Williams JH, Filer A, Salmon M, Buckley CD, Middleton J: Monocytes/macrophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation. Arthritis Res Ther 2010, 12:R161.
24. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
25. Kaneko K, Miyabe Y, Takayasu A, Fukuda S, Miyabe C, Ebisawa M, Yokoyama W, Watanabe K, Imai T, Muramoto K, Terashima Y, Sugihara T, Matsushima K, Miyasaka N, Nanki T: Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis. Arthritis Res Ther 2011, 13:R158.
26. Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N: Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol 2001, 167:5381-5385.
27. Uehara S, Grinberg A, Farber JM, Love PE: A role for CCR9 in T lymphocyte development and migration. J Immunol 2002, 168:2811-2819.
28. Inglis JJ, Simelyte E, McCann FE, Criado G, Williams RO: Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc 2008, 3:612-618.
29. Sato A, Watanabe K, Kaneko K, Murakami Y, Ishido M, Miyasaka N, Nanki T: The effect of synthetic retinoid, Am80, on T helper cell development and antibody production in murine collagen-induced arthritis. Mod Rheumatol 2010, 20:244-251.
30. Tubo NJ, Wurbel MA, Charvat TT, Schall TJ, Walters MJ, Campbell JJ: A systemically-administered small molecule antagonist of CCR9 acts as a tissue-selective inhibitor of lymphocyte trafficking. PLoS One 2012, 7:e50498.
31. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, Miyasaka N: Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol 2004, 173:7010-7016.
32. Miyabe Y, Miyabe C, Iwai Y, Takayasu A, Fukuda S, Yokoyama W, Nagai J, Jona M, Tokuhara Y, Ohkawa R, Albers HM, Ovaa H, Aoki J, Chun J, Yatomi Y, Ueda H, Miyasaka M, Miyasaka N, Nanki T: Necessity of lysophosphatidic acid receptor 1 for development of arthritis. Arthritis Rheum 2013, 65:2037-2047.
33. Vicari AP, Figueroa DJ, Hedrick JA, Foster JS, Singh KP, Menon S, Copeland NG, Gilbert DJ, Jenkins NA, Bacon KB, Zlotnik A: TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity 1997, 7:291-301.
34. Chu PS, Nakamoto N, Ebinuma H, Usui S, Saeki K, Matsumoto A, Mikami Y, Sugiyama K, Tomita K, Kanai T, Saito H, Hibi T: C-C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice. Hepatology 2013, 58:337-350.
35. Nakamoto N, Ebinuma H, Kanai T, Chu PS, Ono Y, Mikami Y, Ojiro K, Lipp M, Love PE, Saito H, Hibi T: CCR9+ macrophages are required for acute liver inflammation in mouse models of hepatitis. Gastroenterology 2012, 142:366-376.
36. Tak PP, Balanescu A, Tseluyko V, Bojin S, Drescher E, Dairaghi D, Miao S, Marchesin V, Jaen J, Schall TJ, Bekker P: Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis 2013, 72:337-344.
37. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP: A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:2387-2392.
38. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D, Tak PP: Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008, 58:1931-1939.
39. van Kuijk AW, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ, Rouzier R, Verschueren PC, van de Leij C, Maas M, Kraan MC, Tak PP: CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2010, 69:2013-2016.
40. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S: T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature 1993, 361:79-82.
41. Wipke BT, Allen PM: Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 2001, 167:1601-1608.
42. Solomon S, Rajasekaran N, Jeisy-Walder E, Snapper SB, Illges H: A crucial role for macrophages in the pathology of K/B x N serum-induced arthritis. Eur J Immunol 2005, 35:3064-3073.
43. de Saint-Vis B, Vincent J, Vandenabeele S, Vanbervliet B, Pin JJ, Aït-Yahia S, Patel S, Mattei MG, Banchereau J, Zurawski S, Davoust J, Caux C, Lebecque S: A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998, 9:325-336.